MARKET

PCRX

PCRX

Pacira BioSciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.61
-1.42
-2.29%
After Hours: 60.61 0 0.00% 16:15 12/04 EST
OPEN
62.15
PREV CLOSE
62.03
HIGH
62.18
LOW
60.13
VOLUME
313.07K
TURNOVER
--
52 WEEK HIGH
68.08
52 WEEK LOW
27.46
MARKET CAP
2.63B
P/E (TTM)
21.34
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32 Annual Virtual Healthcare Conference at 11:30 AM ET on Tuesday, December 1, 2020. Live audio of the virtual event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
GlobeNewswire · 11/24 12:30
Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference
PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference at 11:30 AM ET on Tuesday, December 1, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira         Pacira BioSciences, Inc. (NASDAQ: PCRX) is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
GlobeNewswire · 11/24 12:30
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
Pacira (PCRX) Gets European Commission Approval for Exparel
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
Zacks · 11/19 15:08
Pacira's postsurgical pain med Ok'd in Europe
The European Commission has granted marketing authorization to Pacira BioSciences' (PCRX) EXPAREL (bupivacaine liposome injectable suspension) as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults,
Seekingalpha · 11/18 13:08
Pacira Receives European Commission Approval Of EXPAREL For Treatment Of Postsurgical Pain
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve
Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve · 11/18 12:32
Pacira Receives European Commission Approval for EXPAREL(R) (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery--
GlobeNewswire · 11/18 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCRX. Analyze the recent business situations of Pacira BioSciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCRX stock price target is 66.38 with a high estimate of 83.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 381
Institutional Holdings: 50.92M
% Owned: 117.21%
Shares Outstanding: 43.44M
TypeInstitutionsShares
Increased
90
2.68M
New
73
245.36K
Decreased
83
3.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Director
David Stack
President
Max Reinhardt
Chief Financial Officer
Charles Reinhart
Chief Administrative Officer/Secretary
Kristen Williams
Other
Charles Laranjeira
Other
Dennis McLoughlin
Other
Roy Winston
Lead Director/Independent Director
Paul Hastings
Director
Christopher Christie
Independent Director
Laura Brege
Independent Director
Mark Froimson
Independent Director
Yvonne Greenstreet
Independent Director
Mark Kronenfeld
Independent Director
John Longenecker
Independent Director
Gary Pace
Independent Director
Andreas Wicki
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PCRX
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.